ArticleFrontiers in pharmacology2022
PD-1 inhibitor-based adverse events in solid tumors: A retrospective real-world study.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 2 syntheses or guidelines pooled it, 11 citations in OpenAlex.
- Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials.BMC gastroenterology · 2024Pooled it
- Immune Checkpoint Inhibitors and Cardiotoxicity: A Comparative Meta-Analysis of Observational Studies and Randomized Controlled Trials.Journal of the American Heart Association · 2024Pooled it
- Risk Factors and Comparative Safety of Anti-PD-1 Combination Therapies in Advanced Melanoma: A Nationwide Real-World Cohort Study From China.Cancer medicine · 2026Article
- A multidimensional investigation of myelosuppression associated with sintilimab: integrating pharmacovigilance signal mining with real-world clinical evidence.Frontiers in pharmacology · 2026Article
- Neoadjuvant tislelizumab plus nab-paclitaxel and carboplatin for triple-negative breast cancer: a multicenter, open-label, phase II cTRIO study.EClinicalMedicine · 2026Article
- Exposure-response relationship of sintilimab in advanced gastric cancer: insights from time-dependent pharmacokinetics and biomarker integration for precision immunotherapy.Frontiers in pharmacology · 2026Review
- Sintilimab-induced delayed-onset toxic epidermal necrolysis in a patient with gastric carcinoma: a case report and literature review.Frontiers in oncology · 2026Article
- From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs.Pharmaceuticals (Basel, Switzerland) · 2025Article
- Association between reactive cutaneous capillary endothelial proliferation and the efficacy of camrelizumab in esophageal cancer: a retrospective cohort study.Journal of thoracic disease · 2025Article
- Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies.Frontiers in nutrition · 2025Review
- Predictive factors and outcomes of immune-related adverse events in Chinese patients treated with immune checkpoint inhibitors: a real-world retrospective study.Frontiers in immunology · 2025Article
- Reactive cutaneous capillary endothelial proliferations of the eyelids induced by camrelizumab: A case report.Biomedical reports · 2024Article
- Tislelizumab: an effective treatment option for early-stage triple-negative breast cancer.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2024Article
- Toxicity spectrum and risk factors for chemo-immunotherapy in locally advanced or metastatic lung cancer.Clinical and experimental immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.